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Abstract
Background: Multi-drug resistant Plasmodium falciparum is a major obstacle to malaria control and is emerging as a
complex phenomenon. Mechanisms of drug evasion based on the intracellular extrusion of the drug and/or modification of
target proteins have been described. However, cellular mechanisms related with metabolic activity have also been seen in
eukaryotic systems, e.g. cancer cells. Recent observations suggest that such mechanism may occur in P. falciparum.
Methodology/Principal Findings: We therefore investigated the effect of mefloquine exposure on the cell cycle of three P.
falciparum clones (3D7, FCB, W2) with different drug susceptibilities, while investigating in parallel the expression of four
genes coding for confirmed and putative drug transporters (pfcrt, pfmdr1, pfmrp1 and pfmrp2). Mefloquine induced a
previously not described dose and clone dependent delay in the intra-erythrocytic cycle of the parasite. Drug impact on cell
cycle progression and gene expression was then merged using a non-linear regression model to determine specific drug
driven expression. This revealed a mild, but significant, mefloquine driven gene induction up to 1.5 fold.
Conclusions/Significance: Both cell cycle delay and induced gene expression represent potentially important mechanisms
for parasites to escape the effect of the antimalarial drug.
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Introduction
Plasmodium falciparum malaria remains a major disease burden in
the developing world [1], chemotherapy being the foremost
available tool for its control. Efficacious malaria treatment is
presently dependent on the efficacy of artemisinin combination
therapy (ACT), the global replacement of the previous mainstays,
chloroquine and sulfadoxine-pyrimethamine [1,2]. Unfortunately,
recent data suggests that P. falciparum resistance to ACT might be
presently developing, both to its long half-life components but also
– and worryingly – against the artemisinin based components
[3,4]. The latter phenomenon has been mainly defined as an in vivo
significant decrease in parasite reduction rate, manifested clinically
by markedly longer parasite clearance times [5]. The molecular
basis of this phenomenon is unclear, starting from the fact that
most of these observations are not associated with altered
artemisinin IC50s in vitro [3]. It is conceivable that this
phenomenon is related with other observations by us [6] and
others [7,8] showing that antimalarials can interfere with the cell
cycle development of the parasite, potentially constituting a
general first step towards high grade resistance to antimalarial
drugs.
Drug resistance has been widely associated with the action of
efflux pumps, able to transport drugs out of the relevant cellular
compartment, and thereby displacing them from their molecular
targets [9]. This action is expected to be potentiated through an
increase in the availability of transporter proteins through
enhanced gene transcriptional activity. In P. falciparum two tran-
sporters have been robustly associated with antimalarial resistance:
PfCRT (chloroquine resistance transporter), a drug metabolite
superfamily transporter coded by the pfcrt gene (MAL7P1.27)
[10,11], and the Pgh (P-glycoprotein homologue, coded by pfmdr1
(PFE1150w)) an ATP-binding cassette (ABC) transporter super-
family member [12]. Two other ABC transporters potentially
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homologues of the multidrug resistance-associated protein (MRP)
type [13,14,15] coded by the pfmrp1 (PFA0590w) and pfmrp2
(PFL1410c) genes. Polymorphisms in these drug transporters have
been associated with altered in vitro and/or in vivo responses to
ACT components [16,17,18,19,20,21], indicating that their
common action might constitute a basis for wide range multidrug
resistance phenotypes able to manage the new combinational
therapy challenges faced by the parasite. Besides single nucleotide
polymorphisms (SNPs), enhanced locus expression can drive
decreased drug sensitivity, a phenomenon well documented for
pfmdr1, where gene duplication events are strongly associated to
mefloquine (MQ) resistance [22,23] and lumefantrine decreased
sensitivity [24].
The synthetic arylaminoalcohol MQ constitutes one of the
central partner drugs in artemisinin combination therapy, widely
used in South East Asia and South America. In SE Asia, the in vivo
delayed clearance has been observed not only in artesunate
monotherapy explorative regimens, but also associated to the
regular mefloquine-artesunate ACT [3].
We hypothesize that the observed clearance delay is associated
with this phenomena, contributing for a survival advantage in a
fraction of the parasite infection, by allowing an extended time for
the induction and expression of key drug transporters, leading to a
pivotal decreased intracellular drug exposure in the first phase of
the treatment course.
Using MQ as a relevant and convenient reference ACT
antimalarial, we have focused on monitoring changes in the cell
cycle progression rate of three P. falciparum clones with different
MQ susceptibilities, while in parallel detecting variations in
transcript abundance of the pfmdr1, pfcrt, pfmrp1 and pfmrp2 genes.
Results
Parasites genetic characterization
We have studied in parallel three P. falciparum clones, one MQ
sensitive (W2) and two (3D7 and FCB) with decreased sensitivity.
The pfmdr1, pfcrt, pfmrp1 and pfmrp2 ORF were fully sequenced to
determine the genetic variability between the clones. The three
clones, show two different main pfmdr1 polymorphisms: a single
nucleotide polymorphism at amino acid position 86 (N86 in 3D7,
86Y in W2 and FCB) and gene copy number variation (W2 and
3D7 harbouring one copy [25], with FCB carrying two copies
[23]). Numerous single nucleotide polymorphism differences were
seen in the three remaining genes (GenBank accession numbers:
GU797309, GU797310, GU797311, GU797312, GU797315,
GU797316).
Plasmodium falciparum cell cycle progression alterations
driven by mefloquine
In vitro MQ 50% inhibitory concentration (IC50) of W2, 3D7 and
FCB clones were in average from 6 independent assays 1063.3nM,
50616.9nM and 50614.1nM respectively. As for IC99 the average
results was 44613.9nM, 146636.1nM, 146650.6nM for W2, 3D7
and FCB respectively. These concentrations were used for
challenging the clones in the assay performed.
Exposure to MQ induced an unexpected and unambiguous
delay in the cell cycle progression of the three tested parasites, as
evaluated by Giemsa staining under light microscopy for the four
counted stages (Figure 1). The degree of delay effect was clone
dependent.
At MQ IC99 a pronounced morphology arrest was seen in the
three clones remaining essentially at the experimental initial ring
Figure 1. Stage morphology development throughout time upon MQ exposure. Parasite stage percentage (Y axis) of W2, 3D7 and FCB
clones with continuous exposure at MQ IC50 and MQ IC99 throughout 48 hours time course (X axis). Four morphological stages were differentiated
using light microscope: early rings (brown), late rings/early trophozoites (orange), trophozoites (light green) and schizonts (dark green).
doi:10.1371/journal.pone.0012408.g001
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indicated the presence of viable cells, an observation supported for
all tested parasites by their growth recovery 7–10 days after drug
withdrawal (Figure S1).
Each gene has its own stage morphology expression profile,
which once induced by drugs, it was previously shown that the
expression is strictly correlated with the cell morphology [26,27].
The MQ induced cell morphology delay was also detectable
through the analysis of the transcript accumulation patterns
(Figure 2, green and red curves). Applying the described non-
linear regression model to the cycle (figure 3), significant
differences in the degree of cell morphology progression were
seen with MQ IC99 exposure in the three clones (p,0.05; figure 4:
red lines). The calculated rate at IC50, compared to control was
clone dependent. The effect was less pronounced in W2 parasites
with approximately 15% delay (p=0.23) vs. ,40% for the MQ
tolerant clones FCB and 3D7 (p,0.01) (Figure 4 and Table 1).
Similar cell cycle morphology delay events were also observed
upon quinine exposure (IC50 and IC90) in exploratory 12 hour
follow up assay (Figure S2).
Basal gene expression of transporter genes in W2, 3D7
and FCB
The pfmdr1, pfcrt, pfmrp1 and pfmrp2 cell cycle patterns of relative
transcript abundance from control (i.e. non drug exposed)
experiments for the reference 3D7 clone were similar to the
available data at PlasmoDB [28] (Figure 2, black curves), using as
endogenous control seryl-tRNA synthetase gene. In brief, pfmdr1, pfcrt
and pfmrp2 displayed the lowest levels of expression at approxi-
mately 24 hours (middle/late trophozoite stage) and highest
amplitudes around 42–48 hours post invasion. pfmrp1 revealed
the previously described clearly different expression profile
[29,30], with a peak of expression during the development of
trophozoites (12–24 hours post-invasion).
Comparing relative transcript abundance (R6SD) between the
three clones at onset (Figure 2, time-point 0h), pfmdr1 mRNAs
showed higher levels in the FCB clone (18.1562.84), as compared
to W2 (14.1860.99) and 3D7 (4.9060.21) with a fold difference of
1.3 and 3.7 respectively. Pfcrt showed to be less expressed in the
W2 (3.8660.15) compared with 3D7 (7.4061.90) and FCB
(6.1060.88) with a fold difference of 0.5 and 0.63 respectively. As
for the mrp genes, pfmrp2 gene showed higher expression for 3D7
(8.4061.95) compared with W2 (5.0660.13) and FCB
(3.8161.03) with a fold difference of 1.7 and 2.2 respectively
while pfmrp1 at time-point 0 the results was 3.5 fold difference
between FCB (0.00769
E-4) and W2 (0.00261
E-4) and 1.75 fold
comparing with 3D7 (0.00466
E-4).
Specific drug transporter genes induction by mefloquine
The fact that the drug exposure led to a proliferative delay in
the parasites stage created a new challenge on how to differentiate
gene transcription levels affected by cell morphology from the
Figure 2. Drug transporter gene expression throughout time upon MQ exposure. Parasites cell cycle time course of drug transporters gene
expression at basal level (control, black line) and after exposure to MQ IC50 (green lines) and MQ IC99 (red lines). X axis represent time-points in hours
and Y axis relative gene expression quantification using pf07_0073 as endogenous control gene. Error bars represent standard deviation from 3 in
vitro replicates.
doi:10.1371/journal.pone.0012408.g002
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studied genes. We solved this challenge through two approaches:
(1) From the few possible comparative time-points (control vs. MQ
exposure time-points that had statistically non distinguishable
parasite morphology proportion differences (p.0.05)), transcript
abundance values were compared. The levels of significant gene
expression modulation, within each clone upon MQ exposure,
ranged from 0.6 to 5.8 fold: pfmdr1 (0.6–1.5 fold), pfcrt (0.8–1.3
fold), pfmrp2 (0.8–2.7 fold) and pfmrp1 with the highest MQ driven
induction (0.7–5.8) (Table 2). (2) To complement this limited
comparative point by point verification of drug direct action,
which gave rise to few analyzable points, another analytical
approach based on a non-linear regression analysis of gene
expression over time was conducted for the MQ IC50 experiments.
The calculated fold difference confirmed that the drug exposure
was generally associated with mild changes in the expression of the
genes (figure 5). Considering each gene at IC50 exposure: (a) The
pfmdr1 gene, was significantly more induced in the less MQ
sensitivity clones 3D7 (1.35 fold, p=0.029) and FCB (1.49 fold,
p,0.001), than in the more sensitive W2 (1.23 fold). Comparisons
between the two less sensitive parasites showed that FCB can
induce this gene significantly more than 3D7 (p=0.003). (b) As for
pfmrp1, our data show no statistical difference between the clones.
(c) Concerning pfcrt gene, the W2 and 3D7 parasites appear to lack
the capacity to significantly induce pfcrt upon MQ exposure (1.06
fold and 0.92 fold) compared to FCB (1.25 fold). (d) Pfmrp2,
appears to significantly induce the less MQ sensitivity clones 3D7
(1.32 fold, p=0.003) and FCB (1.46 fold, p=0.023) compared
with W2 (0.96 fold).
Discussion
Upon continuous MQ exposure we have documented a dose
dependent delay of the parasite cell cycle, particularly among the
two MQ less sensitive P. falciparum clones (3D7 and FCB). This
observation prompts the discussion of its biological importance in
terms of drug resistance response.
Mechanistically, the phenomenon of drug resistance is essen-
tially associated with a decrease in the number of effective
opportunities for the therapeutic drug to effectively engage to its
target(s). Below a certain threshold of interaction rate, the
pharmacodynamic effect of the drug will be reduced to a degree
that makes it clinically ineffective (hence associated to a treatment
failure). This can be achieved in the cell by decreasing drug
concentration in the target cellular compartment through the
action of transmembrane transporters. To this a reduced
availability of the target can be added, particularly through a
decrease in metabolic activity, potentially related with a slow down
of the cell cycle.
In several clinically relevant biological systems – notoriously in
cancer cells - drug exposure leads to a noticeable slowing down in
cell cycle progression, even to the point of stalling [31,32]. In
parallel, drug driven cell cycle arrest in P. falciparum has been
consistently described by us and others for several antimalarial
drugs [6,7] including MQ [8] and very recently chloroquine [33].
P. falciparum dormant states are essentially refractory to antima-
larial action [6] presumably due to its low metabolic activity status.
Upon these observations, we speculate that the observed cell cycle
delay behavior might functionally constitute a first stage towards
Figure 3. Non linear regression equation I (for cell morphology) and II (for gene transcripts). y0=offset, corresponding to the initial
(experimental to) status of the parameter under analysis (e.g. number of parasites at ring stage); a=wave amplitude; b=wave period (the reciprocal
wave frequency); b
21=wave frequency; c=wave phase; x=time; d=damping constant factor (to account to dampening variations in amplitude of
gene expression). cm: cell morphology; gt: gene transcripts.
doi:10.1371/journal.pone.0012408.g003
Figure 4. Effect of MQ in P.falciparum stage development. Wave form smoothing function best fitted over the early ring stage cell count
(Figure 1, brown color). The wave frequency value (time needed to complete a cell cycle) for each fitted function (control, MQ IC50 and IC99) was used
for the ratio calculation delay between treated and non treated parasite cultures (Table 1). Statistical comparisons (t-tests) of treatment effects
(control vs. MQ IC50 and IC99) were performed with the associated error of wave frequency value of different experiments per clone compared with
control.
doi:10.1371/journal.pone.0012408.g004
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clones to full recover growth, after 48 hours of intense MQ IC99
exposure, in different recrudescence time indirectly supports this
suggestion.
The capacity to delay the intra-erythrocytic developmental
cycle could therefore be an operational contributor for drug
resistance, particularly when considering drugs with short half-
lives, like artemisinins and quinine. Such a response could help the
parasite to withstand the effects of the drug at its peak serum
concentration, increasing the chances of survival as the drug
concentration rapidly decreases in the circulatory system, due to
elimination. The delay in the cycle might also be of importance for
allowing time for a parallel action: the specific induction of drug
transporters able to reduce the intra-cellular (or intra-compart-
ment) concentrations of the drug. This action can in turn gain time
for the process of metabolic shut off leading to a drug action
refractory state based on the scarcity of drug targets.
Our results show a gene expression induction of generally less
than 2 fold after MQ challenge, suggesting that these genes are
actually inducible by this drug, though to a limited extent. Similar
induction levels have been observed for pfmdr1 (1.7 fold, when
normalized for hsp86) in a northern blot based approach, after a 6h
MQ treatment [34]. This data is also coherent with a trend of low
pfdhfr gene transcriptional response previously reported upon
exposure to the experimental antifolate WR99210 [26], as well as
to chloroquine [27]. It is to note that the observed relatively low
induction of transcription seen in response to MQ does not
exclude more significant responses upon exposure to other
xenobiotics. Accordingly, treatment of the P. falciparum clone
3D7 with phenobarbital (a classical drug elimination inducer) for
48h was associated to an extensive increase in pfmdr1 transcripts,
and to a concordant reduction in drug susceptibility [35].
These observations raise the question on how important mild
changes in gene expression can be in terms of the parasite response
to the drug. When drug resistance is mainly based on direct
modifications of the target, as in the case with antifolates, an
increase in drug quantity of the latter will probably be irrelevant,
since it is unlikely that the number of drug molecules will
overcome the number of target proteins (considering a regular
stoichiometric relationship of action). In the case of transporter
proteins - assuming that they are not themselves targets for the
drug - the situation is markedly different. One protein can
transport a large number of molecules per time unit, and a simple
2 fold increase in this capacity may well have an impact on the
effect of the drug. This is supported by in vivo and in vitro studies
showing that a two fold gene copy number amplification of pfmdr1
significantly affects the parasite response to MQ and other drugs
[22,23,36,37]. Interestingly, the clones herein observed with the
largest induction of transporter genes transcripts in response to
MQ were also the less sensitive to the drug (3D7, FCB), suggesting
a role of increased expression in the overall parasite drug response.
Our observations of significant parasite cycle delay upon drug
exposure points this as a significant confounding factor in the
analysis of parasite drug driven gene expression. Hence, we
propose a simple non-linear regression model as a novel analytical
tool to distinguish drug specific gene induction from the effect of
the time changed gene expression variation associated to the cell
cycle. This approach could be applied in future studies, as well as
revisiting previous data that did not consider the phenomenon of
drug driven cell cycle delay in P. falciparum.
In conclusion, MQ is able to induce expression of pfmdr1, pfcrt,
pfmrp1 and pfmrp2 which, although mild, are potentially significant
in aiding the parasite to evade antimalarial drug action. This
occurs in the context of a prompt MQ driven cell cycle delay that
potentially constitutes a further parallel mechanism for the parasite
populations to avoid, or at least delay, antimalarial action.
Materials and Methods
P. falciparum parasite clones
P. falciparum 3D7 clone was obtained from Prof. D. Walliker
(Department of Animal and population genetics, University of
Edinburgh, UK), while parasite clones W2 (MRA-157) and FCB
(MRA-309) were obtained from Malaria Research and Reference
Reagent Resource Center (MR4, ATCC Massanas Virginia). The
parasite lines were selected on the basis of their sensitivity to
mefloquine hydrochloride (Sigma-AldrichH, St.Louis, MO, USA)
and their genetic background (sequences submitted to GenBank
accession numbers: GU797309, GU797310, GU797311,
GU797312, GU797313, GU797314, GU797315, GU797316).
Drug susceptibility determinations
The inhibitory concentration of 50 and 99% for the three clones
was assessed using an Histidine-Rich Protein 2 based Double-Site
Sandwich Enzyme-Linked Immunosorbent Assay [38] followed by
nonlinear regression analysis (http://malaria.farch.net).
P. falciparum in vitro culture
The parasites were kept in culture using conventional methods
[39] in human O
+ RBCs and Malaria Culture Medium,
containing RPMI 1640 culture medium supplemented with 10%
L-glutamine, 0.05% gentamicine (GibcoH/Invitrogen
TM, Carls-
bad, CA, USA) and 10% human AB
+ serum. Large scale culture
of each clone was produced with 3% parasitaemia in 2.5%
hematocrite and synchronized in early ring stage at least twice by
applying the MACSH system (Miltenyi Biotec, Bergisch Gladbach,
Germany). The batch was then divided for three experiments: one
control culture (no drug added) and two cultures with MQ IC50
and IC99.concentration followed by spreading it in culture plates
(2mL/well). At the time of reinvasion, early rings (time-point 0),
two Giemsa-stained smears were made for examination of
parasites stages, while three replicate wells of parasite culture
were harvested for RNA extraction. This procedure was followed
for the three experiments, in six hour time-point intervals up to
48 hours (total of 9 time-points analyses including time 0). The
smears were fixed with methanol and stained with 5% Giemsa and
visualization under light microscopy (10006magnification). Their
examination included counting 100 parasites, twice per slide (2
slides per time point), distinguishing four main morphological
stages: early rings, late rings/early trophozoites, trophozoites and
Table 1. Cell cycle development and gene expression of
parasites challenged with MQ IC50.
Clones
Cell cycle
progression
%
* (SE)
Pfcrt
%
{ (SE)
pfmdr1
%
{ (SE)
pfmrp2
%
{ (SE)
pfmrp1
%
{ (SE)
W2 85.3 (12.9) 91.5 (5.6) 107.9 (9.5) 81.2 (9.8) 104.9 (11.8)
3D7 64.3 (8.1) 56.6 (16.6) 98.8 (6.4) 96.4 (14.9) 107.3 (22.9)
FCB 61.2 (10.4) 86.1 (6.3) 109.8 (11.2) 107.5 (26.8) 77.5 (24.5)
*- Cell cycle development percentage was calculated as the ratio of the time
needed to complete a cycle obtained from the fitted wave function (Figure 3,
equation I) of control and MQ IC50 experiments (Figure 4).
{- Gene expression percentage was calculated as the ratio of the time needed
to complete a cycle obtained from the fitted damped wave function (Figure 3,
equation II) of control and MQ IC50 experiments (data not shown).
doi:10.1371/journal.pone.0012408.t001
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experiment was performed. The experimental design was equally
applied for the three clones analyzed (W2, 3D7 and FCB).
Molecular analysis
Parasite cultures collected for RNA extraction were centrifuged
at 0.8 g-force for 2 min. 1.85 mL of supernatant were removed
and 150 mL of PBS plus 300 mL of Lysis buffer (Applied
Biosystems
TM, Fresno, CA, USA) were added. The mix was kept
at 220uC until RNA extraction. RNA extraction was carried out
using an ABIPRISMH6100 Nucleic Acid PrepStationH (Applied
Biosystems
TM, Fresno, CA,USA) according to the recommenda-
tions of the manufacturer. Total RNA quality and quantity was
measured using the AgilentRNA 6000 Pico total RNA assay in an
Agilent2100 Bioanalyser
TM (Santa Clara, CA, USA). Sample
concentrations with RNA Integrity Number .5 were normalized
for each clone before cDNA synthesis (High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Fresno, CA,
USA)). Real-time analyses were performed in an ABIPRISMH
7900HT Sequence Detection System (Applied Biosystems
TM,
Fresno, CA, USA) with gene specific MGB TaqManH probes and
primers. TaqManH probes and primers for target gene pfmdr1 were
as previously published [22]. New designs were developed for pfcrt,
pfmrp1, pfmrp2 and for endogenous control gene [30,40] seryl-tRNA
synthetase (PF07_0073) (Table S1). Amplification reactions were
done in quadruplicate in 384 well plates with 10ml containing
TaqManH Gene Expression Mastermix (Applied Biosystems
TM,
Fresno, CA, USA), 300nM of each forward and reverse primer,
100nM of TaqManHprobe and 2 mL of amount-normalized
cDNA. The thermal cycle profile was 50uC for 2 min, 95uC for
10 min and forty cycles of 95uC for 15 s and 60uC for 1 min. The
amplification efficiency (E) was estimated for each gene and used
as a correction factor for relative gene expression quantification.
All experimental threshold cycle values (Ct) were first transformed
to adjust the RNA concentration adding to the Ct value the log2
RNA concentration of each clone. Relative gene expression was
calculated as the ratio (R) between the transformed Ct values of
target gene and internal control reference gene (PF07_0073),
taking in account the amplification efficiency for each gene [41].
Calculations were conducted using the SAS 9.1 system for
Windows
TM.
Determination of the drug exposure specific induction
effect: time-point gene expression fold differences and
the non-linear regression model approach
In order to distinguish the changes in cDNA abundance
associated with the parasite cell cycle progression from the ones
associated with drug exposure, two different approaches were
performed:
I. Direct comparisons. Fold difference in transcript abun-
dance was calculated in control vs. MQ exposed cultures only in
time-points showing a statistically equal fractional composition of
the four microscopically determined stages (Fisher test, df=3,
p.0.05).
II. Non linear regression analysis. A wavefunction applied
tothenumberoftotalparasites ringstage count throughoutall time-
points for each clone (equation I – figure 3) was achieved
(goodnessoffitwasR
2.0.9) (SigmaPlot
TM9.0). Specificparameters
of this function were used to quantify the parasite delays in cell
morphology (cm) imposed by MQ exposure. The wave frequency
(bcm
21) from each fitted function (control, MQ IC50 and MQ IC99
exposed), corresponds to the time needed to complete a cycle and it
was used to calculate the cell cycle delay based in the observation of
the morphology development of the parasite between MQ exposed
(ICn) and control (Rmorphology=b cm
21
ICn/bcm
21
control). Statistical
comparisons (t-tests)were performed withthe associated error of the
wave frequency parameter ‘‘bcm
21’’.
A similar approach, of applying a wave function, was performed
in the gene transcripts data (gt). During the 48 hours exposure to
MQ IC50, the associated delay in the cycle gene expression was
calculated by comparing the wave frequency parameter ‘‘bgt
21’’
(Rgene transcripts=b gt
21
IC/bgt
21
control) obtained through a best fit of
Figure 5. Drug transporter genes induction by MQ IC50. Results appear as fold difference in gene expression normalized with cell cycle stage
development achieved after smoothing the data with wave functions. Error bars represents SE of the difference.
doi:10.1371/journal.pone.0012408.g005
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(equation II – figure 3). Statistical comparisons (t-tests) were
performed with the associated error of the wave frequency
parameter ‘‘bgt
21’’.
The use of these equations allowed us to determine whether the
expression profiles were solely stage-driven, or included a
significant fraction associated with drug exposure:
MQ driven induction fold difference ðÞ
~ Rgene transcripts{Rcell morphology

z1:
By its nature, this approach was only possible to apply to
experimental outputs where sufficient data points were available
for enabling fitting a sine function, being hence only applicable to
gene transcripts data concerning IC50 and not to the IC99 drug
level exposure.
Supporting Information
Figure S1 Cell viability after MQ IC99 exposure. Parasite strains
viability after challenged with continuous MQ IC99 (W2, 44nM;
3D7 and FCB, 146nM) for 48 hours analyzed by Histidine-Rich
Protein 2 Double-Site Sandwich Enzyme-Linked Immunosorbent.
All strains had a growth recovery of 7–10 days after drug
withdrawal. Error bars are SE of rate between day0 HRP2 and
collected day.
Found at: doi:10.1371/journal.pone.0012408.s001 (0.06 MB
PDF)
Figure S2 Cell cycle morphology progressions upon quinine
exposure (IC50 and IC90) after 12 hour follow up. Parasite stage
percentage (Y axis) of W2, FCB and 3D7 strains after 12 hours (X
axis) with continuous exposure of quinine IC50 and IC90. The
counting of the parasites included 100 parasites, twice per slide (2
slides per different ICs exposure), distinguishing four main
morphological stages using light microscope: early rings, late
rings/early trophozoites, trophozoites and schizonts.
Found at: doi:10.1371/journal.pone.0012408.s002 (0.01 MB
PDF)
Table S1 TaqManH probes and primers sequence.
Found at: doi:10.1371/journal.pone.0012408.s003 (0.03 MB
DOC)
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